PL375306A1 - Packaged virus-like particles for use as adjuvants: method of preparation and use - Google Patents

Packaged virus-like particles for use as adjuvants: method of preparation and use

Info

Publication number: PL375306A1
Authority: PL; Poland
Prior art keywords: vlps; antigens; packaged; adjuvants; particles
Prior art date: 2002-06-20

Application number

PL03375306A

Other languages

English (en)

Polish (pl)

Inventor

Martin F. Bachmann

Wolfgang A. Renner

Original Assignee

Cytos Biotechnology Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-20

Filing date

2003-06-20

Publication date

2005-11-28

2003-06-20 Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag

2005-11-28 Publication of PL375306A1 publication Critical patent/PL375306A1/xx

Links

239000002671 adjuvant Substances 0.000 title abstract 2
239000002245 particle Substances 0.000 title abstract 2
239000000427 antigen Substances 0.000 abstract 5
102000036639 antigens Human genes 0.000 abstract 5
108091007433 antigens Proteins 0.000 abstract 5
206010020751 Hypersensitivity Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
230000005867 T cell response Effects 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
238000011260 co-administration Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000005847 immunogenicity Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Gynecology & Obstetrics (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)

PL03375306A 2002-06-20 2003-06-20 Packaged virus-like particles for use as adjuvants: method of preparation and use PL375306A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38989802P	2002-06-20	2002-06-20

Publications (1)

Publication Number	Publication Date
PL375306A1 true PL375306A1 (en)	2005-11-28

Family

ID=30000481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03375306A PL375306A1 (en)	2002-06-20	2003-06-20	Packaged virus-like particles for use as adjuvants: method of preparation and use

Country Status (16)

Country	Link
US (2)	US20040005338A1 (fr)
EP (1)	EP1513552B1 (fr)
JP (1)	JP4598519B2 (fr)
CN (1)	CN1662253A (fr)
AT (1)	ATE489969T1 (fr)
AU (1)	AU2003242742B2 (fr)
BR (1)	BR0311995A (fr)
CA (1)	CA2488856A1 (fr)
DE (1)	DE60335186D1 (fr)
IL (1)	IL164812A0 (fr)
MX (1)	MXPA04011210A (fr)
NZ (1)	NZ537002A (fr)
PL (1)	PL375306A1 (fr)
RU (1)	RU2322257C2 (fr)
WO (1)	WO2004000351A1 (fr)
ZA (1)	ZA200408709B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094409B2 (en) *	2001-01-19	2006-08-22	Cytos Biotechnology Ag	Antigen arrays for treatment of allergic eosinophilic diseases
EP2196217A1 (fr)	2001-09-14	2010-06-16	Cytos Biotechnology AG	Emballage de substances immunostimulantes dans des particules similaires aux virus: procédés de production et utilisations
US20070065906A1 (en) *	2003-03-05	2007-03-22	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Process for producing heterologous protein in e. coli
US20060210588A1 (en) *	2003-03-26	2006-09-21	Cytos Biotechnology Ag	Hiv-peptide-carrier-conjugates
CN100560719C (zh) *	2003-03-26	2009-11-18	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
ES2217967B1 (es) *	2003-03-31	2006-01-01	Consejo Sup. Investig. Cientificas	Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
AU2004255470B2 (en) *	2003-07-10	2010-08-19	Cytos Biotechnology Ag	Packaged virus-like particles
WO2005014110A1 (fr) *	2003-07-22	2005-02-17	Cytos Biotechnology Ag	Liposomes a cpg emballees
ES2307346B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
JP3976742B2 (ja) *	2004-02-27	2007-09-19	江守商事株式会社	インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US7964196B2 (en) *	2004-05-25	2011-06-21	Chimeros, Inc.	Self-assembling nanoparticle drug delivery system
MX2007003171A (es) *	2004-09-21	2007-05-23	Cytos Biotechnology Ag	Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
KR20070059207A (ko) *	2004-10-05	2007-06-11	사이토스 바이오테크놀로지 아게	Ｖｌｐ-항원 컨쥬게이트 및 백신으로서 그의 용도
ES2310062B1 (es) *	2005-07-15	2009-11-13	Bionostra, S.L.	Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
JP5484732B2 (ja) *	2005-12-14	2014-05-07	サイトスバイオテクノロジーアーゲー	過敏症の治療のための免疫賦活性核酸パッケージ粒子
CN100418583C (zh) *	2006-02-21	2008-09-17	朱鸿飞	预防和治疗乳腺炎的药物组合物
JP2009533350A (ja) *	2006-04-07	2009-09-17	キメロス，インコーポレイテッド	Ｂ細胞悪性疾患を処置するための組成物および方法
AU2013204383B2 (en) *	2006-06-12	2016-09-22	Kuros Us Llc	Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
KR101552227B1 (ko)	2006-06-12	2015-09-10	사이토스 바이오테크놀로지 아게	올리고뉴클레오티드를 ｒｎａ 박테리오파지의 바이러스-유사 입자로 패키징하는 방법
JP2009544322A (ja) *	2006-07-27	2009-12-17	リゴサイトファーマシューティカルズインコーポレイテッド	キメラウイルス様粒子
US9439959B2 (en)	2006-07-27	2016-09-13	Takeda Vaccines, Inc.	Chimeric influenza virus-like particles
DK2601969T3 (en)	2006-09-29	2016-04-18	Takeda Vaccines Inc	Norovirus vaccine formulations
AU2007333147B2 (en)	2006-12-12	2013-12-19	Kuros Us Llc	Oligonucleotides containing high concentrations of guanine monomers
CA2683063A1 (fr) *	2007-04-09	2008-10-16	Chimeros, Inc.	Systeme de relargage de medicaments par auto-assemblage de nanoparticules
SG184733A1 (en)	2007-09-18	2012-10-30	Ligocyte Pharmaceuticals Inc	Method of conferring a protective immune response to norovirus
US20100266636A1 (en)	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
US8986597B2 (en) *	2007-10-31	2015-03-24	Corning Incorporated	Low creep refractory ceramic and method of making
WO2009060440A1 (fr) *	2007-11-05	2009-05-14	Mor Research Applications Ltd.	Immunothérapie du cancer anti-rougeole
NO339169B1 (no) *	2008-04-24	2016-11-14	Chemoforma Ltd	Funksjonelt fiskefôr omfattende peptidoglykan og nukleotider
CA2733589C (fr) *	2008-08-08	2021-07-13	Ligocyte Pharmaceuticals, Inc.	Particules similaires a un virus comportant des sequences d'acides amines de capside composites pour une reactivite croisee amelioree
CA2744987C (fr)	2008-12-02	2018-01-16	Chiralgen, Ltd.	Procede pour la synthese d'acides nucleiques modifies par des atomes de phosphore
EP2419143B8 (fr)	2009-04-13	2018-06-27	INSERM - Institut National de la Santé et de la Recherche Médicale	Particules hpv et utilisations associées
WO2010120874A2 (fr)	2009-04-14	2010-10-21	Chimeros, Inc.	Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation
CA2767253A1 (fr)	2009-07-06	2011-01-13	Ontorii, Inc.	Nouveaux precurseurs d'acide nucleique et leurs methodes d'utilisation
EP2496609A4 (fr)	2009-11-03	2013-05-08	Ligocyte Pharmaceuticals Inc	Particules de type viral (vlp) chimériques à base de gag de polypeptide rsv-f et de lentivirus ou alpharétrovirus
RU2440141C1 (ru) *	2010-05-31	2012-01-20	Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу)	Способ регуляции иммуногенности антигена
WO2012039448A1 (fr)	2010-09-24	2012-03-29	株式会社キラルジェン	Groupe auxiliaire asymétrique
EA025417B1 (ru) *	2010-11-22	2016-12-30	Борис Славинович ФАРБЕР	Вакцины с повышенной иммуногенностью и способы их получения
KR101376675B1 (ko) *	2011-04-19	2014-03-20	광주과학기술원	이미징 및 운반 이중기능 나노입자－기반 백신 전달체
TWI454478B (zh) *	2011-05-13	2014-10-01	Academia Sinica	類鐸受體-２增效劑及其用於刺激免疫反應之用途
DK3299030T3 (da)	2011-07-11	2022-09-05	Takeda Vaccines Inc	Parenterale norovirus-vaccineformuleringer
WO2013012758A1 (fr)	2011-07-19	2013-01-24	Ontorii, Inc.	Procédés pour la synthèse d'acides nucléiques fonctionnalisés
EP2747774A4 (fr)	2011-09-09	2015-02-11	Biomed Realty L P	Procédés et compositions de régulation d'un assemblage de protéines virales
CN102512671A (zh) *	2011-12-16	2012-06-27	厦门大学	抗o型口蹄疫的类病毒颗粒疫苗及其制备方法
US9700639B2 (en)	2012-02-07	2017-07-11	Aura Biosciences, Inc.	Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CN103421117B (zh) *	2012-05-16	2016-08-03	李岱宗	一种免疫增强型病毒样颗粒、其表达载体及其制备与应用
CN104684923B (zh) *	2012-07-13	2018-09-28	株式会社新日本科学	手性核酸佐剂
KR102712879B1 (ko)	2012-07-13	2024-10-04	웨이브 라이프 사이언시스 리미티드	키랄 제어
JP6268157B2 (ja)	2012-07-13	2018-01-24	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	不斉補助基
WO2015024992A2 (fr) *	2013-08-22	2015-02-26	Cytos Biotechnology Ag	Traitement de l'asthme
CN120617536A (zh)	2013-09-18	2025-09-12	奥拉生物科学公司	用于诊断和治疗肿瘤的病毒样颗粒缀合物
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10144933B2 (en)	2014-01-15	2018-12-04	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP4137572A1 (fr)	2014-01-16	2023-02-22	Wave Life Sciences Ltd.	Conception chirale
US20150355147A1 (en) *	2014-06-06	2015-12-10	Biogénesis Bagó Uruguay S.A.	High throughput quantification and characterization of foot and mouth disease virus and products thereof
CA2963271A1 (fr)	2014-10-02	2016-04-07	Protiva Biotherapeutics, Inc.	Compositions et methodes d'extinction de l'expression du gene du virus de l'hepatite b
US10251970B1 (en)	2014-12-30	2019-04-09	Zee Company	Air sanitation apparatus for food processing tanks having air agitation piping and methods thereof
EP3368656A4 (fr)	2015-10-30	2019-07-17	The United States of America, as represented by the secretary, Department of Health and Human Services	Thérapie anticancéreuse ciblée
CN108779473A (zh) *	2016-03-16	2018-11-09	法国居里学院	用于制备具有环二核苷酸的病毒颗粒的方法和所述颗粒用于治疗癌症的用途
EP3295956A1 (fr)	2016-09-20	2018-03-21	Biomay Ag	Construction de polypeptide comprenant des fragments d'allergenes
TWI634899B (zh) *	2016-11-22	2018-09-11	國立臺灣大學	包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物
US12246031B2 (en)	2018-02-13	2025-03-11	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
AU2019251421B2 (en)	2018-04-09	2025-05-01	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
CN112639077B (zh) *	2018-08-07	2023-06-20	中国科学院生物物理研究所	活化cd4+ t细胞的方法
CN110257922A (zh) *	2019-07-19	2019-09-20	苏州盛天力离心机制造有限公司	羽毛洗涤脱水一体机
AU2020321021A1 (en) *	2019-07-30	2022-03-10	Verndari, Inc.	Virus-like particle vaccines
JP7072604B2 (ja) *	2020-06-23	2022-05-20	アンスティテュ・クリー	環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用
US20230272351A1 (en) *	2020-09-02	2023-08-31	The Regents Of The University Of California	Covid assay controls
CN114632148B (zh) *	2020-12-15	2024-08-09	榕森生物科技(北京)有限公司	病原样抗原疫苗及其制备方法
CN115927400A (zh) *	2022-08-11	2023-04-07	中国动物卫生与流行病学中心	一种含口蹄疫病毒rna片段的假病毒颗粒及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722840A (en) *	1984-09-12	1988-02-02	Chiron Corporation	Hybrid particle immunogens
US5374426A (en) *	1986-09-03	1994-12-20	University Of Saskatchewan	Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5143726A (en) *	1986-12-09	1992-09-01	The Scripps Research Institute	T cell epitopes of the hepatitis B virus nucleocapsid protein
US4918166A (en) *	1987-04-10	1990-04-17	Oxford Gene Systems Limited	Particulate hybrid HIV antigens
US5057540A (en) *	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
EP1690935A3 (fr) *	1990-01-12	2008-07-30	Abgenix, Inc.	Génération d'anticorps xenogéniques
US5334394A (en) *	1990-06-22	1994-08-02	The Regents Of The University Of California	Human immunodeficiency virus decoy
SE9003978D0 (sv) *	1990-12-13	1990-12-13	Henrik Garoff	Dna expressionssystem baserade paa ett virus replikon
GB9114003D0 (en) *	1991-06-28	1991-08-14	Mastico Robert A	Chimaeric protein
US6004763A (en) *	1992-09-11	1999-12-21	Institut Pasteur	Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) *	1992-09-11	1994-12-02	Pasteur Institut	Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
CA2153391C (fr) *	1993-01-11	2000-08-15	Kenneth Rock	Induction de reponses par les lymphocytes t cytotoxiques
AU6172194A (en) *	1993-02-08	1994-08-29	Paravax, Inc.	Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US6015686A (en) *	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
US5904925A (en) *	1993-12-09	1999-05-18	Exner; Heinrich	Adjuvant for antigens, and process for making
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
CA2560114A1 (fr) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Oligonucleotides immunomodulateurs
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5935821A (en) *	1995-01-17	1999-08-10	Board Of Trustees Of The University Of Kentucky	Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5792462A (en) *	1995-05-23	1998-08-11	University Of North Carolina At Chapel Hill	Alphavirus RNA replicon systems
US5770380A (en) *	1996-09-13	1998-06-23	University Of Pittsburgh	Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2288129A1 (fr) *	1997-05-01	1998-11-12	Chiron Corporation	Utilisation de particules de type viral en tant qu'adjuvants
ATE370740T1 (de) *	1997-05-20	2007-09-15	Ottawa Health Research Inst	Verfahren zur herstellung von nukleinsäurekonstrukten
AU732468B2 (en) *	1997-06-23	2001-04-26	Ludwig Institute For Cancer Research	Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US6054312A (en) *	1997-08-29	2000-04-25	Selective Genetics, Inc.	Receptor-mediated gene delivery using bacteriophage vectors
BR9907855A (pt) *	1998-02-12	2001-04-24	Immune Complex Corp	Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal
ATE305507T1 (de) *	1998-05-14	2005-10-15	Coley Pharm Gmbh	Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
AU773204C (en) *	1998-08-10	2005-05-19	Antigenics Llc	Compositions of CPG and saponin adjuvants and methods thereof
US5962636A (en) *	1998-08-12	1999-10-05	Amgen Canada Inc.	Peptides capable of modulating inflammatory heart disease
DK1135162T3 (da) *	1998-11-30	2009-01-19	Cytos Biotechnology Ag	Ordnet molekylær præsentation af allergener, fremstillingsfremgangsmåde samt anvendelse
US6977245B2 (en) *	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
UA77152C2 (en) *	1999-09-25	2006-11-15		Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
AU781812B2 (en) *	2000-01-13	2005-06-16	Antigenics, Inc.	Innate immunity-stimulating compositions of CPG and saponin and methods thereof
US20010044416A1 (en) *	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2407897A1 (fr) *	2000-05-05	2001-11-15	Cytos Biotechnology Ag	Jeu ordonne d'antigenes moleculaires
EP1322287B1 (fr) *	2000-09-28	2006-03-22	Chiron Corporation	Microparticules de transport d'acides nucleiques heterologues
MXPA03003408A (es) *	2000-10-18	2005-06-30	Glaxosmithkline Biolog Sa	Vacunas.
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
EP2196217A1 (fr) *	2001-09-14	2010-06-16	Cytos Biotechnology AG	Emballage de substances immunostimulantes dans des particules similaires aux virus: procédés de production et utilisations
WO2004007538A2 (fr) *	2002-07-17	2004-01-22	Cytos Biotechnology Ag	Reseaux d'antigenes moleculaires
MXPA04012010A (es) *	2002-07-18	2005-03-07	Cytos Biotechnology Ag	Conjugados de hapteno-portador que comprende particulas similares a virus, y usos de los mismos.
KR20050027168A (ko) *	2002-07-19	2005-03-17	사이토스 바이오테크놀로지 아게	그렐린-캐리어 컨쥬게이트
CN100560719C (zh) *	2003-03-26	2009-11-18	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物

2003
- 2003-06-20 AT AT03760672T patent/ATE489969T1/de not_active IP Right Cessation
- 2003-06-20 AU AU2003242742A patent/AU2003242742B2/en not_active Ceased
- 2003-06-20 DE DE60335186T patent/DE60335186D1/de not_active Expired - Lifetime
- 2003-06-20 US US10/465,811 patent/US20040005338A1/en not_active Abandoned
- 2003-06-20 CA CA002488856A patent/CA2488856A1/fr not_active Abandoned
- 2003-06-20 RU RU2005101206/13A patent/RU2322257C2/ru not_active IP Right Cessation
- 2003-06-20 PL PL03375306A patent/PL375306A1/xx not_active Application Discontinuation
- 2003-06-20 BR BR0311995-5A patent/BR0311995A/pt not_active IP Right Cessation
- 2003-06-20 EP EP03760672A patent/EP1513552B1/fr not_active Expired - Lifetime
- 2003-06-20 WO PCT/EP2003/006541 patent/WO2004000351A1/fr not_active Ceased
- 2003-06-20 CN CN038142228A patent/CN1662253A/zh active Pending
- 2003-06-20 MX MXPA04011210A patent/MXPA04011210A/es active IP Right Grant
- 2003-06-20 NZ NZ537002A patent/NZ537002A/en not_active IP Right Cessation
- 2003-06-20 JP JP2004514823A patent/JP4598519B2/ja not_active Expired - Fee Related
2004
- 2004-06-20 IL IL16481204A patent/IL164812A0/xx unknown
- 2004-10-27 ZA ZA200408709A patent/ZA200408709B/en unknown
2010
- 2010-05-28 US US12/790,708 patent/US20110070267A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1513552A1 (fr)	2005-03-16
DE60335186D1 (de)	2011-01-13
WO2004000351A1 (fr)	2003-12-31
JP4598519B2 (ja)	2010-12-15
CA2488856A1 (fr)	2003-12-31
EP1513552B1 (fr)	2010-12-01
US20040005338A1 (en)	2004-01-08
JP2006502979A (ja)	2006-01-26
NZ537002A (en)	2006-06-30
US20110070267A1 (en)	2011-03-24
CN1662253A (zh)	2005-08-31
RU2005101206A (ru)	2005-06-27
AU2003242742B2 (en)	2009-04-30
HK1074578A1 (en)	2005-11-18
IL164812A0 (en)	2005-12-18
MXPA04011210A (es)	2005-02-14
WO2004000351A8 (fr)	2005-02-03
AU2003242742A1 (en)	2004-01-06
RU2322257C2 (ru)	2008-04-20
ZA200408709B (en)	2005-11-18
ATE489969T1 (de)	2010-12-15
BR0311995A (pt)	2005-04-05

Publication	Publication Date	Title
IL164812A0 (en)	2005-12-18	Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2003024481A3 (fr)	2004-06-03	Emballage de substances immunnostimulatrices dans des particules de type virus : procede de preparation et utilisation correspondants
WO2004084939A3 (fr)	2005-03-31	Conjugues porteurs de peptides du vih
Sewell et al.	2008	Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors
IL150602A (en)	2010-12-30	Proteosome influenza vaccine, method for preparing such and use thereof
Martínez-Donato et al.	2016	Protective T cell and antibody immune responses against hepatitis C virus achieved using a biopolyester-bead-based vaccine delivery system
DE602004031017D1 (de)	2011-02-24	Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
WO2002034205A3 (fr)	2002-07-18	Utilisation des proteines du stress pour stimuler la reponse immunitaire
WO2001082963A3 (fr)	2002-04-11	Synchronisation d'epitopes dans des cellules presentant des antigenes
NO20062674L (no)	2006-06-09	Optimalisert uttrykking av HPV58-L1 i gjaer
WO2004084936A8 (fr)	2004-12-16	Microbes modifies vivant en milieu naturel, compositions de vaccins, et procedes d'utilisation correspondants
WO2005089164A3 (fr)	2005-12-01	Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
WO2005009463A3 (fr)	2005-06-02	Vaccins contre les cellules presentatrices de l'antigene et methodes d'utilisation des vaccins
WO2004058157A3 (fr)	2006-11-16	Vaccins a base de levure pour immunotherapie
Mohammed et al.	2016	Cancer vaccines: past, present, and future
WO2005007673A3 (fr)	2007-11-22	Peptides immunogenes
JP2011519869A5 (fr)	2013-05-16
AU2003246373A1 (en)	2004-01-06	Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
Wang et al.	2021	Immune responses to varicella-zoster virus glycoprotein E formulated with poly (lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice
WO2003090687A3 (fr)	2005-01-27	Utilisation de proteines de choc thermique pour renforcer la reponse immunitaire
WO2008082719A3 (fr)	2008-08-21	Système de fourniture combinée de vlp de papillomavirus humain/gène, et utilisation de celui-ci en tant que vaccin pour la prophylaxie et l'immunothérapie de maladies infectieuses et de tumeurs
Lu et al.	2020	Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles
AR041515A1 (es)	2005-05-18	Vacuna a dna contra el virus de papiloma humano
Guillen et al.	2013	Virus-like particles as nanovaccine candidates
Zhu et al.	2025	A therapeutic multi-epitope protein vaccine targeting HPV16 E6 E7 elicits potent tumor regression and cytotoxic immune responses

Legal Events

Date	Code	Title	Description
2012-12-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)